氘瑞米德韋

氘瑞米德韋
臨床資料
商品名（英語：Drug nomenclature）	民得維
其他名稱	VV116, JT001, mindeudesivir, renmindevir
給藥途徑	口服
法律規範狀態
法律規範	中：Rx（附條件使用）; 美：研究用藥物;
識別資訊
	IUPAC命名法 [(2R,3R,4R,5R)-5-(4-amino-5-deuteriopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-bis(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate; ;
CAS號	2647442-33-7
PubChem CID	163358784;
ChemSpider	115285279;
UNII	MF2PS6XPS4;
化學資訊
化學式	C24H30N5O7
摩爾質量	500.53 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES [2H]c2cc([C@]1(C#N)O[C@H](COC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@H]1OC(=O)C(C)C)n3ncnc(N)c23;
	InChI InChI=InChI=1S/C24H31N5O7/c1-12(2)21(30)33-9-16-18(34-22(31)13(3)4)19(35-23(32)14(5)6)24(10-25,36-16)17-8-7-15-20(26)27-11-28-29(15)17/h7-8,11-14,16,18-19H,9H2,1-6H3,(H2,26,27,28)/t16-,18-,19-,24+/m1/s1/i7D; Key:RVSSLHFYCSUAHY-QXMJNOOVSA-N;

氘瑞米德韋，(英語：Deuremidevir)，又稱VV116，是一種用於治療輕至重度2019冠狀病毒病的藥物^[1]。

VV116是一種氘化的氫溴酸瑞德西韋，2020年11月，包括武漢病毒研究所和 Vigonvita 的成員在內的一個研究小組在一份預印本中首次描述了這種結構^[2]。它在 2022 年完成了三期臨床^[3]。2022年10月至2023年1月在中國大陸進行的一項單獨的3期臨床試驗結果表明，與安慰劑相比，VV116可以縮短患有輕度至中度疾病的非住院成年人的2019冠狀病毒疾病症狀持續時間，非劣於奈瑪特韋/利托那韋^[4]。2023年1月，中國國家藥品監督管理局有條件地批准了該藥物的上市^[5]。

2023年11月，為應對病毒突變和感染特徵的變化，世衛組織調整了其治療指南。除了其他變化，除了臨床試驗，建議不要使用氘瑞米德韋治療2019冠狀病毒病^[6]。

2022年，一份研究顯示，氘瑞米德韋在小鼠模型中能有效抑制呼吸道合胞病毒^[7]。目前，該藥物還在進行治療呼吸道合胞病毒感染的臨床試驗^[8]。

參考資料

^ 倪思潔. 我国两款口服抗新冠病毒创新药附条件获批上市. 科學網. 2023-01-29 [2025-01-06] （中文）.
^ Yin W, Luan X, Li Z, Xie Y, Zhou Z, Liu J, Gao M, Wang X, Zhou F, Wang Q, Wang Q. Structural basis for repurpose and design of nucleoside drugs for treating COVID-19. bioRxiv. November 2020. S2CID 226263471. doi:10.1101/2020.11.01.363812.
^ Cao Z, Gao W, Bao H, Feng H, Mei S, Chen P, Gao Y, Cui Z, Zhang Q, Meng X, Gui H, Wang W, Jiang Y, Song Z, Shi Y, Sun J, Zhang Y, Xie Q, Xu Y, Ning G, Gao Y, Zhao R. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19. The New England Journal of Medicine. February 2023, 388 (5): 406–417. PMC 9812289 . PMID 36577095. doi:10.1056/NEJMoa2208822.
^ Fan, Xiaohong; Dai, Xiahong; Ling, Yun; Wu, Lihua; Tang, Lingling; Peng, Chunxian; Huang, Chaolin; Liu, Hongyan; Lu, Hongzhou; Shen, Xinghua; Zhang, Wei; Wang, Furong; Li, Guangming; Li, Ming; Huang, Yanming; Zhang, Hongying; Li, Minghui; Ren, Fei; Li, Yuanyuan; Liu, Chenfan; Zhou, Zhiguo; Sun, Wei; Yi, Yongxiang; Zhou, Daming; Gao, Hainv; Pan, Qi; Liu, Hongde; Zhao, Jiang; Ding, Zhen; Ma, Yingmin; Li, Wei; Wang, Quanhong; Wang, Xicheng; Bai, Yichun; Jiang, Xiangao; Ma, Juan; Xie, Bingying; Zhang, Kui; Li, Lanjuan. Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study. The Lancet Infectious Diseases. 2024-02, 24 (2): 129–139. PMID 38006892. doi:10.1016/S1473-3099(23)00577-7.
^ 陳竹沁. 君实生物国产新冠药民得维（VV116）获批，由李兰娟院士牵头. 澎湃新聞. 2023-01-29 [2025-01-06] （中文）.
^ WHO updates its guidance on treatments for COVID-19. BMJ (Press release). 9 November 2023.
^ Zhang, Ruxue; Zhang, Yumin; Zheng, Wei; Shang, Weijuan; Wu, Yan; Li, Ning; Xiong, Jun; Jiang, Hualiang; Shen, Jingshan; Xiao, Gengfu; Xie, Yuanchao; Zhang, Leike. Oral remdesivir derivative VV116 is a potent inhibitor of respiratory syncytial virus with efficacy in mouse model. Signal Transduction and Targeted Therapy. 2022-04-16, 7 (1). PMC 9012943 . PMID 35429988. S2CID 35429988. doi:10.1038/s41392-022-00963-7 .
^ 药物临床试验登记与信息公示平台（搜索“氘瑞米德韦”）. www.chinadrugtrials.org.cn.

[1] 倪思潔. 我国两款口服抗新冠病毒创新药附条件获批上市. 科學網. 2023-01-29 [2025-01-06] （中文）.

[2] Yin W, Luan X, Li Z, Xie Y, Zhou Z, Liu J, Gao M, Wang X, Zhou F, Wang Q, Wang Q. Structural basis for repurpose and design of nucleoside drugs for treating COVID-19. bioRxiv. November 2020. S2CID 226263471. doi:10.1101/2020.11.01.363812.

[3] Cao Z, Gao W, Bao H, Feng H, Mei S, Chen P, Gao Y, Cui Z, Zhang Q, Meng X, Gui H, Wang W, Jiang Y, Song Z, Shi Y, Sun J, Zhang Y, Xie Q, Xu Y, Ning G, Gao Y, Zhao R. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19. The New England Journal of Medicine. February 2023, 388 (5): 406–417. PMC 9812289 . PMID 36577095. doi:10.1056/NEJMoa2208822.

[4] Fan, Xiaohong; Dai, Xiahong; Ling, Yun; Wu, Lihua; Tang, Lingling; Peng, Chunxian; Huang, Chaolin; Liu, Hongyan; Lu, Hongzhou; Shen, Xinghua; Zhang, Wei; Wang, Furong; Li, Guangming; Li, Ming; Huang, Yanming; Zhang, Hongying; Li, Minghui; Ren, Fei; Li, Yuanyuan; Liu, Chenfan; Zhou, Zhiguo; Sun, Wei; Yi, Yongxiang; Zhou, Daming; Gao, Hainv; Pan, Qi; Liu, Hongde; Zhao, Jiang; Ding, Zhen; Ma, Yingmin; Li, Wei; Wang, Quanhong; Wang, Xicheng; Bai, Yichun; Jiang, Xiangao; Ma, Juan; Xie, Bingying; Zhang, Kui; Li, Lanjuan. Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study. The Lancet Infectious Diseases. 2024-02, 24 (2): 129–139. PMID 38006892. doi:10.1016/S1473-3099(23)00577-7.

[5] 陳竹沁. 君实生物国产新冠药民得维（VV116）获批，由李兰娟院士牵头. 澎湃新聞. 2023-01-29 [2025-01-06] （中文）.

[6] WHO updates its guidance on treatments for COVID-19. BMJ (Press release). 9 November 2023.

[7] Zhang, Ruxue; Zhang, Yumin; Zheng, Wei; Shang, Weijuan; Wu, Yan; Li, Ning; Xiong, Jun; Jiang, Hualiang; Shen, Jingshan; Xiao, Gengfu; Xie, Yuanchao; Zhang, Leike. Oral remdesivir derivative VV116 is a potent inhibitor of respiratory syncytial virus with efficacy in mouse model. Signal Transduction and Targeted Therapy. 2022-04-16, 7 (1). PMC 9012943 . PMID 35429988. S2CID 35429988. doi:10.1038/s41392-022-00963-7 .

[8] 药物临床试验登记与信息公示平台（搜索“氘瑞米德韦”）. www.chinadrugtrials.org.cn.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]